{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:47:34Z","timestamp":1791917254867,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end\u2010stage renal disease (ESRD) receiving renal replacement therapy (RRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare thrombotic and safety outcomes in patients receiving either vitamin K antagonists (VKAs) or apixaban 2.5\u2009mg twice daily in the context of ESRD and RRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Retrospective service evaluation comparing bleeding and thrombotic outcomes in patients treated with apixaban 2.5\u2009mg BD or VKA in a tertiary anticoagulation clinic. Trough anti\u2010Xa levels of apixaban patients were reviewed. Clinical features and outcomes were reviewed using electronic patient records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty\u2010five VKA and 33 apixaban patients were included in the analysis. There were no major bleeds in the apixaban cohort compared with 4 (7.3%) in the VKA cohort (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20092.667,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.102). No difference in time to major or clinically relevant non\u2010major bleeding (CRNMB) was found (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20091.252,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.263). Rates of thrombotic events (all stroke) were 1\n                      <jats:italic>vs<\/jats:italic>\n                      . 3 (1.1 and 7.1 events\/100 patient\u2010years) for VKA and apixaban, respectively (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20093.291,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.070). Only one stroke was related to AF. Eighty\u2010four of 85 trough anti\u2010Xa levels analysed were below the upper limit of normal of the reference range for the general population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our results suggest similar outcomes with VKA and apixaban in those receiving RRT, indicating apixaban may be a viable second\u2010line treatment option in those for whom VKA may not be appropriate. Further investigation into the safety of the apixaban 5\u2010mg regimen is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70805","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:46:17Z","timestamp":1788507977000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparing outcomes using low\u2010dose apixaban and anti\u2010Xa monitoring and vitamin K antagonists in patients with renal replacement therapy"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-3174","authenticated-orcid":false,"given":"John K.","family":"Bartoli\u2010Abdou","sequence":"first","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"},{"name":"Institute of Pharmaceutical Science King's College London  London UK"},{"name":"Department of Pharmacy Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-4621","authenticated-orcid":false,"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Vernon","sequence":"additional","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"},{"name":"Department of Pharmacy Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Collings","sequence":"additional","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"},{"name":"Institute of Pharmaceutical Science King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubonphan","family":"Chaichana","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Jibril","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Kumar","sequence":"additional","affiliation":[{"name":"Renal Department Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Breen","sequence":"additional","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0486","authenticated-orcid":false,"given":"Andrew J.","family":"Doyle","sequence":"additional","affiliation":[{"name":"Department of Haemostasis &amp; Thrombosis Guy's &amp; St Thomas' NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"e_1_2_10_3_1","unstructured":"NICE.Atrial fibrillation: diagnosis and management\u2014NICE guideline [NG196]. National Institute of Health & Care Excellence (NICE)2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.08.006"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0006602020"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14134"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010016\u20100368\u20106"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15\u20101719"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023644"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101450\u20108178"},{"key":"e_1_2_10_14_1","unstructured":"Bristol\u2010Myers Squibb &Pfizer.Eliquis 5mg film\u2010coated tablets: summary of product characteristics. Electronic Medicines Compendium.2017. Updated 03\/2017. Accessed 23\/08 2017.https:\/\/www.medicines.org.uk\/emc\/medicine\/27220"},{"key":"e_1_2_10_15_1","unstructured":"ParkerKPowerABernesYet alClinical practice guideline: anticoagulation for atrial fibrillation in adults with advanced kidney disease. UK Kidney Association. Accessed 17\/06\/2026 2026.https:\/\/www.ukkidney.org\/sites\/default\/files\/documents\/FINAL%20version%20Anticoagulants%20in%20Advanced%20CKD%20NVAF%20guide_Oct2025.pdf"},{"key":"e_1_2_10_16_1","unstructured":"ParkerKPowerABernesY. et al.Clinical Practice Guideline: anticoagulation for venous thromboembolism in adults with advanced kidney disease. UK Kidney Association UK Kidney Association. Accessed 17\/06\/2026 2026.https:\/\/www.ukkidney.org\/sites\/default\/files\/documents\/FINAL%20version%20Anticoagulants%20in%20Advanced%20CKD%20VTE%20guide_Oct2025_1.pdf"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018781853"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.12.020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017694654"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035418"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12083"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13599"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100041\u20101740254"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062779"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000495"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016090980"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.06.030"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882\u2010024\u201003782\u2010w"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.10.014"},{"key":"e_1_2_10_33_1","unstructured":"Food and Drug Administration.FDA Approves Updated Warfarin (Coumadin) Prescribing Information. August 16 2007.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108967.htm(Last accessed on August 4 2014)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70805","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:46:19Z","timestamp":1788507979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":32,"alternative-id":["10.1002\/bcp.70805"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70805","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"bcp.70805"}}